Latest Werewolf Therapeutics News & Updates

See the latest news and media coverage for Werewolf. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Werewolf Therapeutics (Werewolf)

Cancer immunotherapy biotechnology company

werewolftx.com
Headquarters
Watertown, United States
Company type
Public company
Number of employees
22–50
Industry
Pharmaceuticals

Last updated

Latest news about Werewolf Therapeutics (Werewolf)

In short: Werewolf Therapeutics advanced its Ambros merger, shared oncology trial data, and reported a $9.9 million Q3 loss.

Company announcements

Werewolf

Werewolf files S-4 amendment for merger with Ambros

The filing solicits stockholder approval for a merger where Werewolf becomes a subsidiary of Ambros Therapeutics, valued at $500 million.

Unlock all announcements with a

Media coverage

搜狐

Werewolf runs low on cash, merges via reverse acquisition

In August 2026, Nasdaq-listed Werewolf Therapeutics (which was running low on cash and had previously been reported to be considering a sale or merger) announced a reverse merger with Ambros Therapeutics, which specializes in rare disease drugs, raising $150 million simultaneously. Following the merger, Ambros will take the lead, with former Ambros shareholders holding approximately 71.7% of the shares, while former Werewolf shareholders will hold only 6.8%. A so-called reverse merger allows a small company to go public directly by using an already listed company's status, avoiding the need to go through the IPO queue process again—although the shares are significantly diluted...

Law360

3 Firms Build Biotech Merger With $150M In Private Funding - Law360

Biopharmaceutical company Werewolf Therapeutics and clinical-stage biotechnology firm Ambros Therapeutics have agreed to merge in an all-stock deal built by three law firms, and includes...

Unlock all articles with a

Never miss news about Werewolf

Track Werewolf and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.